Back to top
more

Incyte (INCY)

(Real Time Quote from BATS)

$52.00 USD

52.00
1,144,735

-0.38 (-0.73%)

Updated Apr 23, 2024 02:36 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Allogene Therapeutics (ALLO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ekta Bagri headshot

Biotech Stock Roundup: BIIB's Q1 Results, ARWR Up on Data, INCY & BLUE Offer Updates

by Ekta Bagri

Earnings and pipeline updates from Biogen (BIIB) and Arrowhead (ARWR) are they key highlights of the biotech sector.

Incyte (INCY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for Molina Healthcare (MOH) in Q1 Earnings?

by Zacks Equity Research

Molina Healthcare's (MOH) Q1 results are likely to have benefited from the strong performance of its Medicaid and Medicare businesses, partly offset by rising operating costs.

Incyte (INCY) Opzelura Gets EC Nod for Non-Segmental Vitiligo

by Zacks Equity Research

Incyte (INCY) gets EC approval for Opzelura (cream formulation of ruxolitinib) for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PBE

MorphoSys Up on Finishing Early Enrolment in Myelofibrosis Study

by Zacks Equity Research

As MorphoSys (MOR) completes enrolment before schedule in a late-stage study evaluating therapy in myelofibrosis patients, the top-line data from this study is now expected early.

Incyte (INCY) Down 9.6% so Far in 2023 on Recent Setbacks

by Zacks Equity Research

Incyte (INCY) shares are down 9.6% in the year so far on pipeline setbacks.

Biotech Stock Roundup: VKTX, BMEA, ITCI Soar on Study Data, INCY Faces Setback

by Zacks Equity Research

Pipelines updates from Viking Therapeutics (VKTX) and Intra-Cellular (ITCI) are the key highlights for the biotech sector.

Incyte's (INCY) Pemazyre Gets Approval to Treat MLNs in Japan

by Zacks Equity Research

Incyte (INCY) receives approval for treating myeloid or lymphoid neoplasms using Pemazyre (pemigatinib) in Japan.

Company News for Mar 27, 2023

by Zacks Equity Research

Companies in The News Are: SQ,INCY,JPM,WFC

Incyte (INCY) Gets CRL for Jakafi Extended-Release Tablets

by Zacks Equity Research

The FDA issues a complete response letter to Incyte's (INCY) extended-release tablet formulation of Jakafi drug for the treatment of myelofibrosis, polycythemia vera and graft-versus-host disease.

Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval

by Zacks Equity Research

Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.

Incyte (INCY) Receives FDA Approval for Skin Cancer Treatment

by Zacks Equity Research

Incyte (INCY) gets accelerated approval for retifanlimab-dlwr for the treatment of adults with metastatic or recurrent locally advanced merkel cell carcinoma.

Incyte (INCY) Vitiligo Drug Povorcitinib Positive in Phase II

by Zacks Equity Research

Incyte (INCY) announces positive data on povorcitinib and Opzelura for the treatment of nonsegmental vitiligo.

Incyte (INCY) Down 8.3% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biotech Stock Roundup: PTGX Gains on Study Data, BMRN Faces Setback & More

by Zacks Equity Research

Pipeline and regulatory updates from Protagonist (PTGX) and BioMarin (BMRN) are the key highlights from the biotech sector during the past week.

Mesoblast's (MESO) GVHD Drug BLA Gets FDA Priority Tag, Stock Up

by Zacks Equity Research

Mesoblast (MESO) announces the FDA acceptance for review of the resubmitted biological license application for remestemcel-L for the treatment of children under 12 with steroid-refractory acute graft versus host disease. Stock gains on Wednesday, following the news.

Incyte (INCY) Discontinues Jakafi Combo Myelofibrosis Study

by Zacks Equity Research

Incyte (INCY) decides to scrap the LIMBER-304 study evaluating the efficacy and safety of parsaclisib plus Jakafi for myelofibrosis (MF) following an independent data monitoring committee recommendation.

Biotech Stock Roundup: MRNA Q4 Earnings, REGN's Updates, CYTK Receives Setback

by Zacks Equity Research

Earnings from Moderna (BIIB) and updates from Regeneron (REGN) are the key highlights from the biotech sector during the past week.

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Syndax (SNDX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Devoid of marketed drugs, investors' focus will be on Syndax Pharmaceuticals' (SNDX) pipeline progress when it reports its fourth-quarter earnings.

Incyte (INCY) Reports Positive Long-Term Data From HS Study

by Zacks Equity Research

Incyte's (INCY) povorcitinib shows sustained and durable efficacy across all treatment arms in the open-label extension period of the phase II HS study.

Incyte's (INCY) Q4 Earnings, Revenues Top on Jakafi, Opzelura

by Zacks Equity Research

Incyte (INCY) reports better-than-expected Q4 results on strong demand for lead drug Jakafi and recently approved Opzelura.

Incyte (INCY) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Incyte (INCY) delivered earnings and revenue surprises of 5.08% and 4.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?